ArticleAnnals of translational medicine2019
The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism.
Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Incidence and risk factors of VTE in lung cancer: a meta-analysis.Annals of medicine · 2024Pooled it
- Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Article
- Prognostic indicators and nomograms for postoperative survival among younger patients with non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery.Translational lung cancer research · 2025Article
- Circulating tumor DNA predicts venous thromboembolism in patients with cancers.Journal of thrombosis and haemostasis : JTH · 2025Article
- Predicting a failure of postoperative thromboprophylaxis in non-small cell lung cancer: A stacking machine learning approach.PloS one · 2025Article
- Case Report: Unraveling a web of clots: marantic endocarditis as a paraneoplastic manifestation of lung cancer.Frontiers in oncology · 2025Article
- Cancer-associated thromboses in non-small cell lung cancer patients withContemporary oncology (Poznan, Poland) · 2025Article
- Association of baseline plasma D-dimer and platelets with progression-free survival in patients with stage IV non-small cell lung cancer treated with anti-PD-1 antibody.Translational lung cancer research · 2024Article
- Exploring the impact of variable power outputs on the efficacy and safety during microwave ablation for lung carcinoma: a real-world study.Journal of thoracic disease · 2024Article
- The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma.Current oncology (Toronto, Ont.) · 2023Article
- Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review.BMJ open respiratory research · 2023Review
- Nomogram model combined thrombelastography for venous thromboembolism risk in patients undergoing lung cancer surgery.Frontiers in physiology · 2023Article
- Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?Frontiers in medicine · 2023Review
- Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.ESMO open · 2022Article
- Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors.Current problems in cancer · 2022Review
- Leukocyte as an Independent Predictor of Lower-Extremity Deep Venous Thrombosis in Elderly Patients With Primary Intracerebral Hemorrhage.Frontiers in neurology · 2022Article
- Explainable Machine Learning Model to Prediction EGFR Mutation in Lung Cancer.Frontiers in oncology · 2022Article
- Postpartum septic pelvic thrombophlebitis and ovarian vein thrombosis after caesarean section: a rare case report.BMC pregnancy and childbirth · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to investigate the incidence of venous thromboembolism (VTE) in epidermal growth factor receptor (EGFR) mutations patients with lung adenocarcinoma, to provide clinical basis for the perioperative prevention and treatment of VTE in patients with lung cancer.
methodsThis study included patients with invasive lung adenocarcinoma confirmed by pathology from July 2016 to March 2018 after surgical pulmonectomy in Thoracic Surgery Department of Beijing Chaoyang Hospital. All enrolled patients were tested for relevant gene mutations. All patients were classified as adenocarcinoma subtypes by the 2011 International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS) and European Respiratory Society (ERS). Patients were divided into the VTE group and the control group according to whether VTE occurred postoperatively. Baseline data, gene test results, operative data and tumor pathology data between the two groups were compared.
resultsAccording to the inclusion criteria, a total of 323 patients underwent lung cancer surgery were analyzed in this study, including 148 males and 175 females, aged from 25 to 82 years old. Postoperative VTE occurred in 33 patients, with an incidence of 10.2%. Compared the baseline data, there were significant differences in age and BMI between the two groups, but no significant differences in other indicators. Comparing the results of postoperative genetic tests, the cases of exon 18, 19, 20, 21, 30, 31 mutation, exon 18 and 20 mixed mutation and exon 20 and 21 mixed mutation were 5, 42, 6, 57, 1, 3, 1 and 1. The total EGFR mutation rate in the enrolled patients was 36.2% (117/323). Among them, the proportion of EGFR mutation in the VTE group was significantly higher than that in the non-VTE group (60.6%
conclusionsThe incidence of VTE was 10.2% in patients with invasive lung adenocarcinoma without prophylactic anticoagulant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.